Cambridge Innovation Capital
VC Fund
Cambridge, United Kingdom
Cambridge Innovation Capital (CIC) is a leading venture capital firm specialising in early-stage deep technology and life sciences companies. The firm is headquartered in Cambridge, England, and currently has approximately £600 million assets under management. The firm has a twelve-year track record of investing in science-driven companies, with a portfolio spanning cancer therapies, genomic diagnostics, surgical robotics, artificial intelligence, semiconductors and quantum computing. Portfolio companies have collectively raised over £3.2 billion and created more than 2,750 jobs during CIC's period of investment, and four portfolio companies have reached unicorn status. Founded in 2013, CIC is a preferred investor for the University of Cambridge, operating under a long-standing collaboration agreement that provides the team with privileged access to the most promising investment opportunities emerging from the University.
- Total investments:
- 119
- Last investment:
- Lead investor:
- 37%
- Fund size:
- $332M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Cambridge Innovation Capital invests in
Stages Cambridge Innovation Capital invests in
Countries Cambridge Innovation Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Seed
- $2M–$31M
- Series A
- $2.6M–$73M
- Series B
- $8.2M–$68M
Investment Focus
Industry
- Biotechnology 24 (20%)
- Health Care 14 (12%)
- Medical 11 (9%)
- Therapeutics 11 (9%)
- Software 10 (8%)
Stage
- Series A 27 (23%)
- Series B 24 (20%)
- Seed 17 (14%)
- Series C 7 (6%)
- Funding Round 7 (6%)
Country
- United Kingdom 43 (36%)
- United States 4 (3%)
- Ireland 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anne Horgan
Partner
|
Partner | Total investments: 3 | Find email | |
Damian Crowther
Entrepreneur In Residence
|
Entrepreneur In Residence | Total investments: 0 | Find email | |
Edward Benthall
Chairman
|
Chairman | Total investments: 2 | Find email | |
Humphrey Battcock
Independent Non-executive Director
|
Independent Non-executive Director | Total investments: 0 | Find email | |
Ian Jauncey
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany. | $125M / Series B / Oct 14, 2026 | ||
| TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M / Seed / Jun 23, 2026 | ||
| Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures. | $12.7M / Seed / Apr 07, 2026 | ||
| Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils. | $87.1M / Series A / Mar 24, 2026 | ||
|
BeyondMath
|
AI-first approach to simulating the physical world | $10M / Seed / Feb 25, 2026 | |
| T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. . | $32M / Series A / Nov 13, 2025 | ||
| Sortera Bio operates as a biotechnology company. Sortera is committed to providing revolutionary solutions in biologics discovery. | $10.2M / Pre-Seed / Jun 05, 2025 | ||
| TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $31M / Seed / Mar 05, 2025 | ||
| Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany. | $30M / Series A / Feb 07, 2025 | ||
| Forefront RF is a fabless semiconductor company. | $20.8M / Series A / Nov 07, 2024 | ||
| See all 119 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Cambridge Innovation Capital invest in?
Cambridge Innovation Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 119 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Cambridge Innovation Capital invest in?
Cambridge Innovation Capital typically joins rounds of $2M–$31M at Seed, $2.6M–$73M at Series A and $8.2M–$68M at Series B. These are whole funding-round sizes, not Cambridge Innovation Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Cambridge Innovation Capital took part in.
How do I contact Cambridge Innovation Capital?
Public channels for Cambridge Innovation Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cambridge Innovation Capital?
The team at Cambridge Innovation Capital includes Anne Horgan (Partner), Damian Crowther (Entrepreneur In Residence) and Edward Benthall (Chairman), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
